Series DD round generates $200mm for Intarcia

Intarcia Therapeutics Inc. (drug delivery) raised an impressive $200mm in a Series DD equity financing led by first-time backer RA Capital, which was joined by new and current shareholders including Farallon Capital Management, Foresite Capital, Franklin Templeton, Fred Alger Management, New Leaf Venture Partners, Quilvest, and three returning institutional investors. The new money will support Phase III trials of Intarcia’s Type II diabetes compound ITCA650. The company anticipates filing for regulatory approval in late 2015 or early 2016. In November 2012, it closed a $210mm round, one of the largest private biotech financings in more than two decades.